US20200281551A1 - Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof - Google Patents
Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof Download PDFInfo
- Publication number
- US20200281551A1 US20200281551A1 US16/882,456 US202016882456A US2020281551A1 US 20200281551 A1 US20200281551 A1 US 20200281551A1 US 202016882456 A US202016882456 A US 202016882456A US 2020281551 A1 US2020281551 A1 US 2020281551A1
- Authority
- US
- United States
- Prior art keywords
- segment
- train
- head
- pharmaceutical composition
- blood vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003860 storage Methods 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 53
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 86
- 239000000463 material Substances 0.000 claims description 53
- 210000004204 blood vessel Anatomy 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000001569 carbon dioxide Substances 0.000 claims description 42
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 42
- 239000007789 gas Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 11
- 238000003384 imaging method Methods 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000002591 computed tomography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 210000002565 arteriole Anatomy 0.000 claims description 4
- 238000002594 fluoroscopy Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 238000002601 radiography Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 230000007946 glucose deprivation Effects 0.000 abstract description 5
- 208000006443 lactic acidosis Diseases 0.000 abstract description 5
- 230000003472 neutralizing effect Effects 0.000 abstract description 5
- 230000002601 intratumoral effect Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 13
- 238000002583 angiography Methods 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 238000013461 design Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 5
- 239000003229 sclerosing agent Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 208000007474 aortic aneurysm Diseases 0.000 description 3
- 230000005744 arteriovenous malformation Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000010109 chemoembolization Effects 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000007632 sclerotherapy Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 238000002324 minimally invasive surgery Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010108 arterial embolization Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001553 barium compounds Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229940029378 iothalamate Drugs 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 229940029407 ioxaglate Drugs 0.000 description 1
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
- 229960002611 ioxilan Drugs 0.000 description 1
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000004249 mesenteric artery inferior Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- -1 pure ethanol Chemical class 0.000 description 1
- 230000010110 radioembolization Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002628 unsealed source radiotherapy Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0404—X-ray contrast preparations containing barium sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0606—"Over-the-needle" catheter assemblies, e.g. I.V. catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/005—Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/007—Injectors for solid bodies, e.g. suppositories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/007—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M2005/1787—Syringes for sequential delivery of fluids, e.g. first medicament and then flushing liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
Definitions
- the present invention generally relates to a train-like pharmaceutical composition (configuration, or dosage form), a medical apparatus for preparing the pharmaceutical composition, and a medical storage device for sealing and storing the pharmaceutical composition.
- a train-like pharmaceutical composition (configuration, or dosage form)
- a medical apparatus for preparing the pharmaceutical composition and a medical storage device for sealing and storing the pharmaceutical composition.
- the invention will be illustrated, explained and exemplified by releasing the train-like pharmaceutical composition into a blood vessel lumen for the purpose of diagnosis and therapy e.g. embolism and cancer treatment, such as neutralizing intratumoral lactic acidosis combined with glucose deprivation to control tumor; it should be appreciated that the present invention can also be applied to other fields.
- Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. Sclerosis is the thickening of the vessel wall and sealing off the blood flow.
- foam sclerotherapy “foamed sclerosant drugs” are injected into a blood vessel using a pair of syringes, one with sclerosant in it and one with gas such as air.
- the sclerosant drugs such as sodium tetradecyl sulfate or polidocanol are mixed with air or a physiological gas (e.g. carbon dioxide) in a syringe or by using mechanical pumps.
- arteriovenous malformation is an abnormal connection between arteries and veins, bypassing the capillary system.
- Ethanol is a sclerosing agent very good for treating AVM. Ethanol will harden the endothelial lining of vessels, denature proteins of the endothelium, and activate the coagulation system to cause a blood clot.
- ethanol administration is not easy to monitor and control. Therefore, ethanol injected into a patient's body may be out of control and flow to an area that causes damage to the tissue in the area.
- the present invention provides train-like pharmaceutical composition (configuration, or dosage form) which exhibits numerous technical merits such as precise control of “invisible” chemical agent inside a patient's body, maximal and safe tumor control and sclerosant action, among others.
- One aspect of the present invention provides a train-like pharmaceutical composition (configuration, or dosage form) comprising, a head segment and a body segment linearly arranged in series like two adjacent cars of a train.
- a train-like pharmaceutical composition comprising, a head segment and a body segment linearly arranged in series like two adjacent cars of a train.
- the head segment's location can be observed by a human with the aid of an instrument.
- the body segment's location cannot be observed by a human with the aid of the same instrument.
- the body segment's location can be estimated, deduced, calculated, or inferred based on the observed head segment's location.
- the apparatus includes at least (1) a head segment material source, (2) a head material tube (such as a channel within a catheter) for delivering the head segment material from said head segment material source directly into the blood vessel lumen, (3) a body segment material source, and (4) a body material tube (such as a channel within a catheter) for delivering the body segment material from said body segment material source directly into the blood vessel lumen.
- Still another aspect of the invention provides a medical storage device comprising a tube for storing the train-like pharmaceutical composition as described above.
- a further aspect of the invention provides a method of treating a blood vessel and cells around the blood vessel.
- the method comprises (i) providing the train-like pharmaceutical composition as described above; (ii) administrating the pharmaceutical composition into a patient's body; (iii) observing the head segment's location with the raid of an instrument; and (iv) estimating, deducing, calculating or inferring the body segment's location based on the observed head segment's location, wherein the body segment's location cannot be directly observed by a human with the aid of the same instrument.
- FIG. 1 schematically shows a train-like pharmaceutical composition being administrated into a patient in accordance with an exemplary embodiment of the present invention.
- FIG. 2 schematically illustrates a first design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention.
- FIG. 3 schematically illustrates a second design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention.
- FIG. 4 schematically illustrates a third design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention.
- FIG. 5 schematically shows two designs of medical storage device comprising a tube for storing the train-like pharmaceutical composition in accordance with an exemplary embodiment of the present invention.
- FIG. 6 schematically illustrates a method of treating a blood vessel and cells around the blood vessel in accordance with an exemplary embodiment of the present invention.
- the train-like pharmaceutical composition may further include a tail segment 3 that can be observed by a human with the aid of the instrument 10 .
- the body segment 2 is sandwiched between the head segment 1 and the tail segment 3 .
- the head segment 1 , the body segment 2 and the tail segment 3 are linearly arranged in series like three consecutive cars of a train. Therefore, the location of the body segment 2 can be estimated or deduced from the observed head segment 1 's location and/or tail segment 3 's location.
- head segment 1 and body segment 2 as described above can be repeated for one or more times to form a (body-head) n configuration or simply (B-H) n configuration.
- B or body stands for body segment 2 ;
- H or head stands for head segment 1 ;
- n is an integer and n ⁇ 2.
- this train-like pharmaceutical composition may further include one more tail segment 3 that can be observed by a human with the aid of instrument 10 , to form a tail-(body-head)n configuration or simply T-(B-H) n configuration, wherein T or tail stands for tail segment; n is an integer and n ⁇ 2.
- the first segment of the train-like pharmaceutical composition that is entered into or administrated into the patient's body is preferably a head segment 1 .
- the first car of the train is preferably a head segment.
- the first car of the train can be a body segment.
- the train-like pharmaceutical composition may be confined within a lumen of a tubular structure 8 having an elongation direction, like a train is confined within a tunnel.
- Tubular structure 8 can be a blood vessel 4 of a human or an animal, a catheter 5 , or a combination thereof.
- “combination” it is intended to mean that the catheter 5 is inserted into the blood vessel 4 and their lumens are connected, joined, combined, or extended from one into another, so as to constitute a continuous passageway for the pharmaceutical composition to move through.
- blood vessel 4 include, but are not limited to, an arteriole, or a blood vessel between an arteriole and its downstream capillaries supplying blood to target cells 40 such as tumor cells 41 .
- a medical apparatus 20 may be used for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen.
- the lumen of tubular structure 8 either blood vessel 4 or catheter 5 , has an internal diameter (or an internal maximal dimension) at a position of the lumen, and any segment 1 / 2 / 3 (head, body, or tail) that is confined at said position has a diameter (or an external maximal dimension) same as said internal diameter (or said internal maximal dimension).
- segment 1 / 2 / 3 at the position fill up the entire space of the lumen at that position.
- segment 1 / 2 / 3 when the lumen is larger at a position, corresponding segment 1 / 2 / 3 at that position will have a larger diameter, but a smaller length along the elongation direction of the lumen.
- instrument 10 examples include, but are not limited to, an X-ray-based imaging apparatus used in computed tomography (CT), radiography, and fluoroscopy; an ultrasound apparatus; a magnetic resonance imaging (MRI) apparatus; or any combination thereof.
- CT computed tomography
- MRI magnetic resonance imaging
- Head segment 1 , body segment 2 and tail segment 3 may be independently of each other in the form of gas, liquid, slurry, or solid, as long as the body segment 2 is not completely dissolved, dispersed or suspended into head segment 1 or tail segment 3 .
- the head segment 1 and the tail segment 3 may be independently of each other a gas such as carbon dioxide, air, nitrogen, oxygen, inert gases, or mixture thereof; a solution (e.g. water solution) of an iodinated contrast agent such as ionic compounds e.g. diatrizoate, metrizoate, iothalamate and ioxaglate; non-ionic compounds e.g.
- Such pharmaceutical composition of the invention may be injected as a radio-opaque or radio-transparent contrast agent into the blood vessel for imaging technique using X-ray based techniques such as fluoroscopy.
- Angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers.
- Such pharmaceutical composition of the invention may be used as radiocontrast agents, a type of medical contrast medium used to improve the visibility of internal bodily structures in X-ray-based imaging techniques such as computed tomography (CT), radiography, and fluoroscopy.
- CT computed tomography
- the train-like pharmaceutical configuration of the invention may include iodine or barium compounds and it improves visibility of an area, known as “contrast enhancing”.
- CO2 angiography is a useful diagnostic tool, particularly in patients who were hypersensitive to iodinated contrast material or whose renal function was compromised.
- CO2 can be used to guide various vascular interventions, including angioplasty and stent placement, transcatheter embolization, and endovascular abdominal aortic aneurysm (AAA) repair, Since CO2 is approximately 20 times more soluble than oxygen, the volume of the gas needs to be adjusted as needed. When injected into a vessel, CO2 bubbles completely dissolve within 2-3 minutes; therefore a larger volume of CO2 will be needed.
- the gas If the gas is trapped in a large abdominal aneurysm, it may persist, allowing gas exchange between the CO2 and nitrogen in the blood, therefore a smaller volume of CO2 will be needed. This exchange may result in colonic ischemia, as a result of occlusion of the inferior mesenteric artery The localized accumulation of gas bubbles may produce a significant gas embolism, particularly in the pulmonary artery.
- the head/tail segment 1 / 3 is a gas such as carbon dioxide
- the body segment 2 is a liquid.
- the liquid include alcohols such as pure ethanol, or ethanol that contains a minimal amount of water, such as less than 1%, 0.1%, or 0.01% of water by weight. It should be appreciated that, when ethanol contacts a human or animal tissue, more or less additional body fluid with water may be introduced into ethanol. Ethanol may have a volume of 0.0001 ⁇ 1 milliliter.
- a therapeutic agent such as a basic substance or basic compound may be dissolved, suspended, or dispersed in ethanol.
- the ethanol may be alkalized.
- the basic substance or alkaline agent include, but are not limited to, sodium ethoxide, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium ethoxide, potassium carbonate, potassium hydrogen carbonate, potassium hydroxide, primary amine, secondary amine, tertiary amine, aliphatic amine, aromatic amine, and the like.
- the basic substance can be present in ethanol in an amount of 0.01-20% or even higher by weigh of the ethanol, depending on the applications and, strength of the basic substance, e.g. basicity.
- the basic substance can be used to kill cancerous cells 40 / 41 .
- neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor.
- Patients may be treated with transarterial chemoembolization (TACE) with local infusion of the basic substance into tumor.
- TACE transarterial chemoembolization
- TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. It combines chemotherapy with embolization (chemoembolization).
- embolization chemoembolization
- small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
- the basic ethanol in the body segment 2 of the invention functions similarly to such embolic particles, except it is for neutralizing intratumoral lactic acidosis combined with glucose deprivation.
- the train-like composition of the invention (CO2 and/or ethanol) can function as an embolus, besides blocking the blood supply to the tumor, also includes an ingredient such as the basic substances to attack the tumor chemically.
- body segment 2 may carry any suitable chemotherapy drug to preform chemoembolization such as TACE.
- Body segment 2 may alternatively or additionally carry a radiopharmaceutical for unsealed source radiotherapy such as radioembolization or selective internal radiation therapy (SIRT).
- Embolization is a minimally invasive surgery that can prevent blood flow to an area of the body, and effectively shrink a tumor or block an aneurysm. The procedure is typically carried out as an endovascular procedure by a radiologist in an interventional suite.
- FIG. 2 schematically shows an exemplary medical apparatus 21 for assembling and delivering the train-like pharmaceutical composition of the invention into a blood vessel lumen.
- Access to the organ under treatment may be acquired by means of a guidewire and catheter(s).
- the position of the correct artery or vein supplying the pathology in question is located by digital subtraction angiography (DSA).
- DSA digital subtraction angiography
- Medical apparatus 21 includes ahead segment material source 211 .
- a head material tube 211 t such as a channel within a catheter, is employed for delivering the head segment material 1 from said head segment material source 211 directly into the blood vessel lumen.
- a body material tube 212 t such as a channel within a catheter, is employed for delivering body segment material 2 from a body segment material source 212 directly into the blood vessel lumen.
- head segment material source 211 may be a CO2 source in the form of a tank or cylinder, filled with 99.99% laboratory-grade CO2.
- the cylinder may be supplied with highly pure gas, a valve, a regulator, a gas gauge, and a metal diaphragm with the regulator set at 18 psi. Because of the risk of injection of large volumes of CO2, the catheter should not be directly connected to the CO2 cylinder, which contains a large volume of CO2 at very high pressure.
- CO2 may be delivered into a vessel using e.g a handheld syringe, by a plastic bag system.
- the plastic bag may be connected to the carbon dioxide cylinder through a 0.2 micrometer filter.
- a 3-way stopcock between the cylinder and the bag allows filling and emptying of the bag with carbon dioxide to remove residual air from the bag.
- a syringe When a syringe is used, it is preferably filled directly from a CO2 cylinder. Sometimes, CO2 should not be aspirated into the syringe because this may cause air contamination. When the syringe has been filled with CO2, its pressure should be reduced to the atmospheric level by quickly opening and closing the stopcock. The CO2-filled syringe should not be left on the table with the stopcock open before injection, because the CO2 in the syringe (which has a CO2 concentration of >99%) is rapidly replaced with air (which has a CO2 concentration of only 0.03%).
- the CO2 injection rate depends on the diameter, length, and flow of the blood vessels being imaged or treated. For an abdominal aortogram or an inferior vena cavogram, 30-40 cc of CO2 may be injected. When imaging aortic branches (celiac, superior mesenteric, renal arteries) or arteries of the lower extremity, 20-30 cc may be used. Because of the low viscosity of the gas, CO2 may be injected through a 3-Fr microcatheter for selective and superselective angiography and for selective arterial embolization.
- the body segment material 2 is produced in situ by mixing two materials 2 a and 2 b . Then, two body material tubes 212 at and 212 bt , such as two channels within a catheter, are employed for delivering body segment materials 2 a and 2 b from body segment material sources 212 a and 212 b directly into the blood vessel lumen. Two materials 2 a and 2 b may be miscible or immiscible, and therefore, body segment 2 may be made of a homogeneous material, or it may be divided into two sub-segments 2 a and 2 b .
- a tail material tube 213 t such as a channel within a catheter, may be employed for delivering tail segment material 3 from a tail segment material source 213 directly into the blood vessel lumen.
- a controller 219 controls the time (timing) and amount of materials 1 , 2 a , 2 b and 3 delivered into the blood vessel lumen so that the segments are linearly arranged in series in the blood vessel lumen like many cars of a train, >>>. . . 3 - 2 b- 2 a- 1 - 3 - 2 b- 2 a- 1 - 3 - 2 b- 2 a- 1 >>>, >>> . . .
- the design of medical apparatus 21 as shown in FIG. 2 may be slightly changed.
- a master catheter 218 is inserted into the blood vessel lumen.
- the head material tube 211 t is connected to the master catheter 218 so that the head segment material 1 from said head segment material source 211 is delivered into the blood vessel lumen through the master catheter 218 .
- body material tubes and tail material tube ( 212 at , 212 bt and 213 t ) are connected to the master catheter 218 so that the body segment materials 2 a , 2 b and tail segment material 3 from their sources 212 a , 212 b and 213 are delivered into the blood vessel lumen through the master catheter 218 .
- the design of medical apparatus 21 as shown in FIG. 3 may also be changed.
- head material tube 211 t body material tubes 212 at , 212 bt and tail material tube 213 t can be removed from the device.
- the train configuration will be formed once the materials 1 , 2 a , 2 b and 3 enter the master catheter 218 .
- a medical storage device 30 includes a tube 31 (soft or rigid, straight or curved) for sealing and storing the train-like pharmaceutical composition as described above.
- storage device 30 includes one or more valves 32 located between the head/tail segment 1 / 3 and the body segment 2 and separating the head/tail segment 1 / 3 and the body segment 2 from each other. In the storage of the pharmaceutical composition, the valves 32 may remain closed. When needed, the valves 32 may be automatically or manually opened, and a pressure may be applied at one end of the tube under control, forcing the train-like pharmaceutical composition to exit from the tube 31 at another end, and enter into the lumen of a catheter or a blood vessel.
- the invention provides a method of treating a blood vessel and cells around the blood vessel.
- the method comprises (i) providing the train-like pharmaceutical composition as described above; (ii) administrating the pharmaceutical composition into a patient's body; (iii) observing the head segment's location with the aid of an instrument; and (iv) estimating, deducing, calculating or inferring the body segment's location based on the observed head segment's location, wherein the body segment's location cannot be directly observed by a human with the aid of the same instrument.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Reproductive Health (AREA)
- High Energy & Nuclear Physics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Acoustics & Sound (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Surgical Instruments (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a train-like pharmaceutical composition (configuration, or dosage form) comprising segments linearly arranged in series like cars of a train. When the pharmaceutical composition is administrated into a patient's body, some of the segments are “visible” to an instrument, but others are not. However, “invisible” segments can be estimated, deduced, calculated, or inferred from “visible” segments. The “invisible” segments can be used for neutralizing intratumoral lactic acidosis combined with glucose deprivation to control tumor, among other applications.
Description
- This application expressly claims all Paris Convention and related priority from U.S. Provisional Application for U.S. Patent Ser. No. 62/476,993 titled “Train-Like Pharmaceutical Configuration and Method Thereof” and filed Mar. 27, 2017, which is incorporated by references as if set forth in its entirety.
- The present invention generally relates to a train-like pharmaceutical composition (configuration, or dosage form), a medical apparatus for preparing the pharmaceutical composition, and a medical storage device for sealing and storing the pharmaceutical composition. Although the invention will be illustrated, explained and exemplified by releasing the train-like pharmaceutical composition into a blood vessel lumen for the purpose of diagnosis and therapy e.g. embolism and cancer treatment, such as neutralizing intratumoral lactic acidosis combined with glucose deprivation to control tumor; it should be appreciated that the present invention can also be applied to other fields.
- Sclerotherapy is a procedure used to treat blood vessels or blood vessel malformations (vascular malformations) and also those of the lymphatic system. Sclerosis is the thickening of the vessel wall and sealing off the blood flow. In foam sclerotherapy, “foamed sclerosant drugs” are injected into a blood vessel using a pair of syringes, one with sclerosant in it and one with gas such as air. The sclerosant drugs such as sodium tetradecyl sulfate or polidocanol are mixed with air or a physiological gas (e.g. carbon dioxide) in a syringe or by using mechanical pumps.
- For example, arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, bypassing the capillary system. Ethanol is a sclerosing agent very good for treating AVM. Ethanol will harden the endothelial lining of vessels, denature proteins of the endothelium, and activate the coagulation system to cause a blood clot. However, in X-ray imaging guided sclerotherapy, ethanol administration is not easy to monitor and control. Therefore, ethanol injected into a patient's body may be out of control and flow to an area that causes damage to the tissue in the area.
- Therefore, there exists a need to overcome the aforementioned problems, as well as a need to conveniently and precisely delivery basic chemical agents to a tumor for neutralizing intraturnoral lactic acidosis combined with glucose deprivation of that tumor. Advantageously, the present invention provides train-like pharmaceutical composition (configuration, or dosage form) which exhibits numerous technical merits such as precise control of “invisible” chemical agent inside a patient's body, maximal and safe tumor control and sclerosant action, among others.
- One aspect of the present invention provides a train-like pharmaceutical composition (configuration, or dosage form) comprising, a head segment and a body segment linearly arranged in series like two adjacent cars of a train. When the pharmaceutical composition is administrated into a patient's body, the head segment's location can be observed by a human with the aid of an instrument. However, the body segment's location cannot be observed by a human with the aid of the same instrument. With the present invention, the body segment's location can be estimated, deduced, calculated, or inferred based on the observed head segment's location.
- Another aspect of the invention provides a medical apparatus for assembling and delivering the train-like pharmaceutical composition as described above into a blood vessel lumen. The apparatus includes at least (1) a head segment material source, (2) a head material tube (such as a channel within a catheter) for delivering the head segment material from said head segment material source directly into the blood vessel lumen, (3) a body segment material source, and (4) a body material tube (such as a channel within a catheter) for delivering the body segment material from said body segment material source directly into the blood vessel lumen.
- Still another aspect of the invention provides a medical storage device comprising a tube for storing the train-like pharmaceutical composition as described above.
- A further aspect of the invention provides a method of treating a blood vessel and cells around the blood vessel. The method comprises (i) providing the train-like pharmaceutical composition as described above; (ii) administrating the pharmaceutical composition into a patient's body; (iii) observing the head segment's location with the raid of an instrument; and (iv) estimating, deducing, calculating or inferring the body segment's location based on the observed head segment's location, wherein the body segment's location cannot be directly observed by a human with the aid of the same instrument.
- The above features and advantages and other features and advantages of the present invention are readily apparent from the following detailed description of the best modes for carrying out the invention when taken in connection with the accompanying drawings.
- The present invention is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings and in which like reference numerals refer to similar elements. All the figures are schematic and generally only show parts which are necessary in order to elucidate the invention. For simplicity and clarity of illustration, elements shown in the figures and discussed below have not necessarily been drawn to scale. Well-known structures and devices are shown in simplified form, omitted, or merely suggested, in order to avoid unnecessarily obscuring the present invention.
-
FIG. 1 schematically shows a train-like pharmaceutical composition being administrated into a patient in accordance with an exemplary embodiment of the present invention. -
FIG. 2 schematically illustrates a first design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention. -
FIG. 3 schematically illustrates a second design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention. -
FIG. 4 schematically illustrates a third design of a medical apparatus for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen in accordance with an exemplary embodiment of the present invention. -
FIG. 5 schematically shows two designs of medical storage device comprising a tube for storing the train-like pharmaceutical composition in accordance with an exemplary embodiment of the present invention. -
FIG. 6 schematically illustrates a method of treating a blood vessel and cells around the blood vessel in accordance with an exemplary embodiment of the present invention. - In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It is apparent, however, to one skilled in the art that the present invention may be practiced without these specific details or with an equivalent arrangement.
- Where a numerical range is disclosed herein, unless otherwise specified, such range is continuous, inclusive of both the minimum and maximum values of the range as well as every value between such minimum and maximum values. Still further, where a range refers to integers, only the integers from the minimum value to and including the maximum value of such range are included. In addition, where multiple ranges are provided to describe a feature or characteristic, such ranges can be combined.
- It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention. For example, when an element is referred to as being “on”, “connected to”, or “coupled to” another element, it can be directly on, connected or coupled to the other element or intervening elements may be present. In contrast, when an element is referred to as being “directly on”, “directly connected to”, or “directly coupled to” another element, there are no intervening elements present.
- As shown in
FIG. 1 , a train-like pharmaceutical composition includes ahead segment 1 and abody segment 2 linearly arranged in series like two adjacent cars of a train. The pharmaceutical composition may be alternatively named as a train-like pharmaceutical configuration, or a train-like pharmaceutical dosage form. When the pharmaceutical composition is administrated into a patient P's body, the location of thehead segment 1 can be observed (e.g. on a display 11) by a human with the aid of aninstrument 10. However, the location of thebody segment 2 cannot be observed, or cannot be observed sufficiently clearly, by a human with the aid of thesame instrument 10. According to the invention, the location ofbody segment 2 can be estimated or deduced from the observed location ofhead segment 1. The train-like pharmaceutical composition may further include atail segment 3 that can be observed by a human with the aid of theinstrument 10. Thebody segment 2 is sandwiched between thehead segment 1 and thetail segment 3. Thehead segment 1, thebody segment 2 and thetail segment 3 are linearly arranged in series like three consecutive cars of a train. Therefore, the location of thebody segment 2 can be estimated or deduced from the observedhead segment 1's location and/ortail segment 3's location. - The arrangement of
head segment 1 andbody segment 2 as described above can be repeated for one or more times to form a (body-head)n configuration or simply (B-H)n configuration. B or body stands forbody segment 2; H or head stands forhead segment 1; and n is an integer and n≥2. As a result, 2n head/body segments in total may be arranged in series like 2n consecutive cars of a train. In some embodiments, this train-like pharmaceutical composition may further include onemore tail segment 3 that can be observed by a human with the aid ofinstrument 10, to form a tail-(body-head)n configuration or simply T-(B-H)n configuration, wherein T or tail stands for tail segment; n is an integer and n≥2. As a result, 2n+1 head/body/tail segments arranged in series like 2n+1 consecutive cars of a train. As shown inFIG. 1 , asegment 1/3 located between twobody segments 2 can be viewed as thetail segment 3 of thefront body segment 2, or viewed as thehead segment 1 of the followingbody segment 2. - In preferred embodiments, the first segment of the train-like pharmaceutical composition that is entered into or administrated into the patient's body is preferably a
head segment 1. In other words, the first car of the train is preferably a head segment. In rare situations, the first car of the train can be a body segment. - As shown in
FIG. 1 , the train-like pharmaceutical composition may be confined within a lumen of a tubular structure 8 having an elongation direction, like a train is confined within a tunnel. Tubular structure 8 can be a blood vessel 4 of a human or an animal, a catheter 5, or a combination thereof. By “combination”, it is intended to mean that the catheter 5 is inserted into the blood vessel 4 and their lumens are connected, joined, combined, or extended from one into another, so as to constitute a continuous passageway for the pharmaceutical composition to move through. Examples of blood vessel 4 include, but are not limited to, an arteriole, or a blood vessel between an arteriole and its downstream capillaries supplying blood to target cells 40 such as tumor cells 41. As will be described in details, amedical apparatus 20 may be used for assembling and delivering the train-like pharmaceutical composition into a blood vessel lumen. The lumen of tubular structure 8, either blood vessel 4 or catheter 5, has an internal diameter (or an internal maximal dimension) at a position of the lumen, and anysegment 1/2/3 (head, body, or tail) that is confined at said position has a diameter (or an external maximal dimension) same as said internal diameter (or said internal maximal dimension). In other words,segment 1/2/3 at the position fill up the entire space of the lumen at that position. For a given volume ofsegment 1/2/3, when the lumen is larger at a position, correspondingsegment 1/2/3 at that position will have a larger diameter, but a smaller length along the elongation direction of the lumen. - Examples of
instrument 10 include, but are not limited to, an X-ray-based imaging apparatus used in computed tomography (CT), radiography, and fluoroscopy; an ultrasound apparatus; a magnetic resonance imaging (MRI) apparatus; or any combination thereof. -
Head segment 1,body segment 2 andtail segment 3 may be independently of each other in the form of gas, liquid, slurry, or solid, as long as thebody segment 2 is not completely dissolved, dispersed or suspended intohead segment 1 ortail segment 3. For example, thehead segment 1 and thetail segment 3 may be independently of each other a gas such as carbon dioxide, air, nitrogen, oxygen, inert gases, or mixture thereof; a solution (e.g. water solution) of an iodinated contrast agent such as ionic compounds e.g. diatrizoate, metrizoate, iothalamate and ioxaglate; non-ionic compounds e.g. iopamidol, ioxilan, iopromide, iodixanol and, ioversol; or any mixture thereof. Such pharmaceutical composition of the invention may be injected as a radio-opaque or radio-transparent contrast agent into the blood vessel for imaging technique using X-ray based techniques such as fluoroscopy. Angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. - Such pharmaceutical composition of the invention may be used as radiocontrast agents, a type of medical contrast medium used to improve the visibility of internal bodily structures in X-ray-based imaging techniques such as computed tomography (CT), radiography, and fluoroscopy. The train-like pharmaceutical configuration of the invention may include iodine or barium compounds and it improves visibility of an area, known as “contrast enhancing”.
- Carbon dioxide is commonly used in angiography. CO2 angiography can be widely used for vascular imaging and endovascular procedures. CO2 is low-risk as it is a natural product with no risk of allergic potential However, it is preferably used below the diaphragm as there is a risk of embolism in neurovascular procedures. CO2 is a negative contrast agent in that it displaces blood when injected intravascularly. Carbon dioxide (CO2) gas can also be used as a contrast agent in the venous circulation to delineate the right heart for evaluation of suspected pericardial effusion. CO2 is safe and well tolerated with peripheral venous injections. CO2 can be used as an intra-arterial contrast agent. With digital subtraction angiography (DSA), CO2 angiography is a useful diagnostic tool, particularly in patients who were hypersensitive to iodinated contrast material or whose renal function was compromised. Moreover, CO2 can be used to guide various vascular interventions, including angioplasty and stent placement, transcatheter embolization, and endovascular abdominal aortic aneurysm (AAA) repair, Since CO2 is approximately 20 times more soluble than oxygen, the volume of the gas needs to be adjusted as needed. When injected into a vessel, CO2 bubbles completely dissolve within 2-3 minutes; therefore a larger volume of CO2 will be needed. If the gas is trapped in a large abdominal aneurysm, it may persist, allowing gas exchange between the CO2 and nitrogen in the blood, therefore a smaller volume of CO2 will be needed. This exchange may result in colonic ischemia, as a result of occlusion of the inferior mesenteric artery The localized accumulation of gas bubbles may produce a significant gas embolism, particularly in the pulmonary artery.
- In some embodiments, the head/
tail segment 1/3 is a gas such as carbon dioxide, and thebody segment 2 is a liquid. Preferred examples of the liquid include alcohols such as pure ethanol, or ethanol that contains a minimal amount of water, such as less than 1%, 0.1%, or 0.01% of water by weight. It should be appreciated that, when ethanol contacts a human or animal tissue, more or less additional body fluid with water may be introduced into ethanol. Ethanol may have a volume of 0.0001˜1 milliliter. - A therapeutic agent such as a basic substance or basic compound may be dissolved, suspended, or dispersed in ethanol. The ethanol may be alkalized. Examples of the basic substance or alkaline agent include, but are not limited to, sodium ethoxide, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium ethoxide, potassium carbonate, potassium hydrogen carbonate, potassium hydroxide, primary amine, secondary amine, tertiary amine, aliphatic amine, aromatic amine, and the like. The basic substance can be present in ethanol in an amount of 0.01-20% or even higher by weigh of the ethanol, depending on the applications and, strength of the basic substance, e.g. basicity. When CO2 is injected into the blood, it is combined with water to produce carbonic acid. As such, there is a possibility that carbonic acid can neutralize the basic substance in ethanol. This should be taken into consideration as a factor, and more amount of basic substance should be included in ethanol to compensate such “loss” by CO2 neutralization.
- The basic substance can be used to kill cancerous cells 40/41. For example, neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor. Patients may be treated with transarterial chemoembolization (TACE) with local infusion of the basic substance into tumor. TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. It combines chemotherapy with embolization (chemoembolization). For example, small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways. The basic ethanol in the
body segment 2 of the invention functions similarly to such embolic particles, except it is for neutralizing intratumoral lactic acidosis combined with glucose deprivation. - In the cancer management application, the train-like composition of the invention (CO2 and/or ethanol) can function as an embolus, besides blocking the blood supply to the tumor, also includes an ingredient such as the basic substances to attack the tumor chemically.
- It should be appreciated that body segment 2 (e.g. ethanol) may carry any suitable chemotherapy drug to preform chemoembolization such as TACE.
Body segment 2 may alternatively or additionally carry a radiopharmaceutical for unsealed source radiotherapy such as radioembolization or selective internal radiation therapy (SIRT). Embolization is a minimally invasive surgery that can prevent blood flow to an area of the body, and effectively shrink a tumor or block an aneurysm. The procedure is typically carried out as an endovascular procedure by a radiologist in an interventional suite. -
FIG. 2 schematically shows an exemplarymedical apparatus 21 for assembling and delivering the train-like pharmaceutical composition of the invention into a blood vessel lumen. Access to the organ under treatment may be acquired by means of a guidewire and catheter(s). The position of the correct artery or vein supplying the pathology in question is located by digital subtraction angiography (DSA). These images are then used as a map for the radiologist to gain access to the correct vessel by selecting an appropriate catheter and/or wire, depending on the “shape” of the surrounding anatomy. Once the artificial emboli of the present invention have been successfully introduced, another set of DSA images may be taken to confirm a successful deployment, except CO2 that does not need this. -
Medical apparatus 21 includes aheadsegment material source 211. Ahead material tube 211 t, such as a channel within a catheter, is employed for delivering thehead segment material 1 from said headsegment material source 211 directly into the blood vessel lumen. Similarly, a body material tube 212 t, such as a channel within a catheter, is employed for deliveringbody segment material 2 from a bodysegment material source 212 directly into the blood vessel lumen. - For example, head
segment material source 211 may be a CO2 source in the form of a tank or cylinder, filled with 99.99% laboratory-grade CO2. The cylinder may be supplied with highly pure gas, a valve, a regulator, a gas gauge, and a metal diaphragm with the regulator set at 18 psi. Because of the risk of injection of large volumes of CO2, the catheter should not be directly connected to the CO2 cylinder, which contains a large volume of CO2 at very high pressure. In a manual mode, CO2 may be delivered into a vessel using e.g a handheld syringe, by a plastic bag system. The plastic bag may be connected to the carbon dioxide cylinder through a 0.2 micrometer filter. A 3-way stopcock between the cylinder and the bag allows filling and emptying of the bag with carbon dioxide to remove residual air from the bag. - When a syringe is used, it is preferably filled directly from a CO2 cylinder. Sometimes, CO2 should not be aspirated into the syringe because this may cause air contamination. When the syringe has been filled with CO2, its pressure should be reduced to the atmospheric level by quickly opening and closing the stopcock. The CO2-filled syringe should not be left on the table with the stopcock open before injection, because the CO2 in the syringe (which has a CO2 concentration of >99%) is rapidly replaced with air (which has a CO2 concentration of only 0.03%).
- The CO2 injection rate depends on the diameter, length, and flow of the blood vessels being imaged or treated. For an abdominal aortogram or an inferior vena cavogram, 30-40 cc of CO2 may be injected. When imaging aortic branches (celiac, superior mesenteric, renal arteries) or arteries of the lower extremity, 20-30 cc may be used. Because of the low viscosity of the gas, CO2 may be injected through a 3-Fr microcatheter for selective and superselective angiography and for selective arterial embolization.
- Sometimes, the
body segment material 2 is produced in situ by mixing twomaterials body material tubes 212 at and 212 bt, such as two channels within a catheter, are employed for deliveringbody segment materials segment material sources materials body segment 2 may be made of a homogeneous material, or it may be divided into twosub-segments tail segment material 3 from a tailsegment material source 213 directly into the blood vessel lumen. Acontroller 219 controls the time (timing) and amount ofmaterials - The design of
medical apparatus 21 as shown inFIG. 2 may be slightly changed. Referring toFIG. 3 , amaster catheter 218 is inserted into the blood vessel lumen. Thehead material tube 211 t is connected to themaster catheter 218 so that thehead segment material 1 from said headsegment material source 211 is delivered into the blood vessel lumen through themaster catheter 218. Similarly, body material tubes and tail material tube (212 at, 212 bt and 213 t) are connected to themaster catheter 218 so that thebody segment materials tail segment material 3 from theirsources master catheter 218. The design ofmedical apparatus 21 as shown inFIG. 3 may also be changed. Referring toFIG. 4 , some or all ofhead material tube 211 t,body material tubes 212 at, 212 bt and tail material tube 213 t can be removed from the device. The train configuration will be formed once thematerials master catheter 218. - Referring to
FIG. 5 , amedical storage device 30 includes a tube 31 (soft or rigid, straight or curved) for sealing and storing the train-like pharmaceutical composition as described above. In some embodiments,storage device 30 includes one ormore valves 32 located between the head/tail segment 1/3 and thebody segment 2 and separating the head/tail segment 1/3 and thebody segment 2 from each other. In the storage of the pharmaceutical composition, thevalves 32 may remain closed. When needed, thevalves 32 may be automatically or manually opened, and a pressure may be applied at one end of the tube under control, forcing the train-like pharmaceutical composition to exit from thetube 31 at another end, and enter into the lumen of a catheter or a blood vessel. - As shown in
FIG. 6 , the invention provides a method of treating a blood vessel and cells around the blood vessel. The method comprises (i) providing the train-like pharmaceutical composition as described above; (ii) administrating the pharmaceutical composition into a patient's body; (iii) observing the head segment's location with the aid of an instrument; and (iv) estimating, deducing, calculating or inferring the body segment's location based on the observed head segment's location, wherein the body segment's location cannot be directly observed by a human with the aid of the same instrument. - In the foregoing specification, embodiments of the present invention have been described with reference to numerous specific details that may vary from implementation to implementation. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense. The sole and exclusive indicator of the scope of the invention, and what is intended by the applicant to be the scope of the invention, is the literal and equivalent scope of the set of claims that issue from this application, in the specific form in which such claims issue, including any subsequent correction.
Claims (20)
1. A train-like pharmaceutical composition (configuration, or dosage form) comprising a head segment and a body segment linearly arranged in series like two adjacent cars of a train,
wherein, when the pharmaceutical composition is administrated into a patient's body, the head segment's location can be observed by a human with aid of an instrument; the body segment's location cannot be observed by a human with the aid of said instrument, but it can be deduced from the observed head segment's location.
2. The train-like pharmaceutical composition according to claim 1 , further comprising a tail segment that can be observed by a human with the aid of said instrument,
wherein the body segment is sandwiched between the head segment and the tail segment,
wherein the head segment, the body segment and the tail segment are linearly arranged in series like three consecutive cars of a train, and
wherein the body segment's location can be deduced from the observed head segment's location and tail segment's location.
3. The train-like pharmaceutical composition according to claim 1 , wherein the head segment and the body segment arrangement is repeated one or more times to form a (body-head)n configuration, wherein n is an integer and n≥2, and 2n head/body segments arranged in series like 2n consecutive cars of a train.
4. The train-like pharmaceutical composition according to claim 3 , further comprising a tail segment that can be observed by a human with the aid of said instrument, to form a tail-(body-head)n configuration, wherein n is an integer and n≥2, and 2n+1 head/body/tail segments arranged in series like 2n+1 consecutive cars of a train.
5. The train-like pharmaceutical composition according to claim 1 , which is confined within a lumen of a tubular structure having an elongation direction (like a train is confined within a tunnel).
6. The train-like pharmaceutical composition according to claim 5 , wherein the lumen has an internal diameter at a position of the lumen, and any segment (head, body, or optional tail) that is confined at said position has a diameter same as said internal diameter.
7. The train-like pharmaceutical composition according to claim 5 , wherein the tubular structure is a blood vessel of a human or an animal, a catheter, or a combination thereof, wherein said combination is defined as the catheter is inserted into the blood vessel and their lumens are connected, joined, or combined.
8. The train-like pharmaceutical composition according to claim 1 , wherein the instrument is an X-ray-based imaging apparatus, an ultrasound apparatus, a magnetic resonance imaging (MRI) apparatus, or any combination thereof.
9. The train-like pharmaceutical composition according to claim 8 , wherein the X-ray-based imaging apparatus is used in computed tomography (CT), radiography, fluoroscopy, or any combination thereof, and the blood vessel is an arteriole, or the blood vessel is between an arteriole and its downstream capillaries supplying blood to target cells such as tumor cells.
10. The train-like pharmaceutical composition according to claim 1 , wherein the body segment is a liquid; the head segment is gas such as carbon dioxide; rand an optional tail segment is a gas such as carbon dioxide.
11. The train-like pharmaceutical composition according to claim 10 , wherein the liquid is an alcohol such as ethanol.
12. The train-like pharmaceutical composition according to claim 11 , wherein a therapeutic agent is dissolved, suspended, or dispersed in the alcohol such as ethanol.
13. The train-like pharmaceutical composition according to claim 12 , wherein the therapeutic agent comprises a basic substance.
14. The train-like pharmaceutical composition according to claim 13 , wherein the basic substance comprises sodium ethoxide, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium ethoxide, potassium carbonate, potassium hydrogen carbonate, potassium hydroxide, primary amine, secondary amine, tertiary amine, aliphatic amine, aromatic amine, or any mixture thereof.
15. The train-like pharmaceutical composition according to claim 11 , wherein the alcohol such as ethanol contains less than 0.1% by weigh of water, and has a volume of 0.0001˜1 milliliter.
16. A medical apparatus for assembling and delivering the train-like pharmaceutical composition of claim 1 into a blood vessel lumen, comprising
a head segment material source,
a head material tube (such as a channel within a catheter) for delivering the head segment material from said head segment material source directly into the blood vessel lumen,
a body segment material source, and
a body material tube (such as a channel within a catheter) for delivering the body segment material from said body segment material source directly into the blood vessel lumen.
17. The medical apparatus according to claim 16 , further comprising a master catheter that can be inserted into the blood vessel lumen, wherein the head material tube is connected to the master catheter so that the head segment material from said head segment material source is delivered into the blood vessel lumen through the master catheter; and wherein the body material tube is connected to the master catheter so that the body segment material from said body segment material source is delivered into the blood vessel lumen through the master catheter.
18. The medical apparatus according to claim 16 , further comprising a controller that controls time and amount of the head and body segment materials delivered into said blood vessel lumen so that the head segment and the body segment are linearly arranged in series in the blood vessel lumen like two adjacent cars of a train.
19. A medical storage device comprising a tube for storing the train-like pharmaceutical composition according to claim 1 .
20. The medical storage device according to claim 19 , further comprising a valve located between the head segment and the body segment and separating the head segment and the body segment from each other.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/882,456 US20200281551A1 (en) | 2017-03-27 | 2020-05-23 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
US18/542,472 US20240138791A1 (en) | 2017-03-27 | 2023-12-15 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762476993P | 2017-03-27 | 2017-03-27 | |
PCT/US2018/024395 WO2018183214A1 (en) | 2017-03-27 | 2018-03-26 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
US201916483441A | 2019-08-04 | 2019-08-04 | |
US16/882,456 US20200281551A1 (en) | 2017-03-27 | 2020-05-23 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/024395 Continuation WO2018183214A1 (en) | 2017-03-27 | 2018-03-26 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
US16/483,441 Continuation US10695018B2 (en) | 2017-03-27 | 2018-03-26 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/542,472 Continuation US20240138791A1 (en) | 2017-03-27 | 2023-12-15 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200281551A1 true US20200281551A1 (en) | 2020-09-10 |
Family
ID=63676914
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/483,441 Active US10695018B2 (en) | 2017-03-27 | 2018-03-26 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
US16/882,456 Abandoned US20200281551A1 (en) | 2017-03-27 | 2020-05-23 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
US18/542,472 Pending US20240138791A1 (en) | 2017-03-27 | 2023-12-15 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/483,441 Active US10695018B2 (en) | 2017-03-27 | 2018-03-26 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/542,472 Pending US20240138791A1 (en) | 2017-03-27 | 2023-12-15 | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof |
Country Status (6)
Country | Link |
---|---|
US (3) | US10695018B2 (en) |
EP (1) | EP3618810A4 (en) |
JP (1) | JP2020515592A (en) |
KR (1) | KR20190135021A (en) |
CN (1) | CN110612096A (en) |
WO (1) | WO2018183214A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113546234B (en) * | 2020-04-24 | 2022-09-20 | 苏州医本生命科技有限公司 | Medicinal preparation with tracing function for vascular intervention and its delivery system |
CN117222405A (en) * | 2021-03-04 | 2023-12-12 | 苏州医本生命科技有限公司 | Ethanol-containing pharmaceutical composition and application thereof |
CN115990111A (en) * | 2021-10-20 | 2023-04-21 | 苏州医本生命科技有限公司 | Chained composition preparation device and preparation method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060062736A1 (en) * | 2003-11-17 | 2006-03-23 | Wright David D I | Therapeutic foam |
WO2009149367A1 (en) * | 2008-06-06 | 2009-12-10 | Medrad, Inc. | Apparatus and methods for delivery of fluid injection boluses to patients and handling harmful fluids |
WO2016028002A1 (en) * | 2014-08-20 | 2016-02-25 | Daewoong Pharmaceutical Co., Ltd. | Process for preparing ertapenem-containing lyophilized formulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687475A (en) * | 1984-06-12 | 1987-08-18 | I-Flow Corporation | Method for sequential intravenous infusion of multiple fluids |
EP0805656B1 (en) * | 1995-01-27 | 2004-05-06 | SciMed Life Systems, Inc. | Embolizing system |
US6511468B1 (en) * | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
US6344027B1 (en) | 1999-12-08 | 2002-02-05 | Scimed Life Systems, Inc. | Needle-less injection apparatus and method |
US6726674B2 (en) * | 2001-09-04 | 2004-04-27 | Jomed Gmbh | Methods for minimally invasive, localized delivery of sclerotherapeutic agents |
JP5212676B2 (en) * | 2003-06-27 | 2013-06-19 | 博道 大井 | Method for producing malignant tumor therapeutic agent |
GB0326768D0 (en) * | 2003-11-17 | 2003-12-24 | Btg Int Ltd | Generation of therapeutic microfoam |
JP2006063008A (en) * | 2004-08-26 | 2006-03-09 | Konica Minolta Medical & Graphic Inc | Liposome formulation for treating cancer and method for producing the same |
US9050401B2 (en) * | 2010-05-19 | 2015-06-09 | Angioadvancements, Llc | System for controlled delivery of medical fluids |
US10149935B2 (en) * | 2006-11-27 | 2018-12-11 | Frank Levy | Delivery system and method for the effective and reliable delivery of controlled amounts of a medical fluid |
US10070888B2 (en) * | 2008-10-03 | 2018-09-11 | Femasys, Inc. | Methods and devices for sonographic imaging |
US9554826B2 (en) * | 2008-10-03 | 2017-01-31 | Femasys, Inc. | Contrast agent injection system for sonographic imaging |
US10130662B2 (en) * | 2013-10-22 | 2018-11-20 | Tulip Endovascular Innovation Limited | Therapeutic agent delivery system and method for arteries |
EP2962681A1 (en) * | 2014-07-03 | 2016-01-06 | Swiss VX Venentherapie und Forschung GmbH | Devices and methods for injectable vascular sclerofoams using a carrier made of human blood and uses thereof |
-
2018
- 2018-03-26 JP JP2019553383A patent/JP2020515592A/en active Pending
- 2018-03-26 CN CN201880021772.XA patent/CN110612096A/en active Pending
- 2018-03-26 KR KR1020197031644A patent/KR20190135021A/en not_active Application Discontinuation
- 2018-03-26 WO PCT/US2018/024395 patent/WO2018183214A1/en unknown
- 2018-03-26 EP EP18776588.8A patent/EP3618810A4/en not_active Withdrawn
- 2018-03-26 US US16/483,441 patent/US10695018B2/en active Active
-
2020
- 2020-05-23 US US16/882,456 patent/US20200281551A1/en not_active Abandoned
-
2023
- 2023-12-15 US US18/542,472 patent/US20240138791A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060062736A1 (en) * | 2003-11-17 | 2006-03-23 | Wright David D I | Therapeutic foam |
WO2009149367A1 (en) * | 2008-06-06 | 2009-12-10 | Medrad, Inc. | Apparatus and methods for delivery of fluid injection boluses to patients and handling harmful fluids |
WO2016028002A1 (en) * | 2014-08-20 | 2016-02-25 | Daewoong Pharmaceutical Co., Ltd. | Process for preparing ertapenem-containing lyophilized formulation |
Non-Patent Citations (2)
Title |
---|
Alexander et al, Estimation of volumes of distribution and intratumoral ethanol concentrations by computed tomography scanning after percutaneous ethanol injection, 1996, Acad Radiol., Jan, 3(1), 49-56 (abstract only). (Year: 1996) * |
Chelales et al, Radiologic-pathologic analysis of increased ethanol localization and ablative extent achieved by ethyl cellulose, 2021, Sci Rep. 11:20700, 27 pages. (Year: 2021) * |
Also Published As
Publication number | Publication date |
---|---|
CN110612096A (en) | 2019-12-24 |
EP3618810A4 (en) | 2021-04-14 |
KR20190135021A (en) | 2019-12-05 |
WO2018183214A1 (en) | 2018-10-04 |
EP3618810A1 (en) | 2020-03-11 |
US10695018B2 (en) | 2020-06-30 |
US20200008764A1 (en) | 2020-01-09 |
US20240138791A1 (en) | 2024-05-02 |
JP2020515592A (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240138791A1 (en) | Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof | |
White Jr et al. | Embolotherapy with detachable silicone balloons: technique and clinical results | |
US8123693B2 (en) | Methods and devices for determining lumen occlusion | |
Baltacıoğlu et al. | Transarterial microcatheter glue embolization of the bronchial artery for life-threatening hemoptysis: technical and clinical results | |
US11576985B2 (en) | Contrast imaging agent with dissolved gas-evolving fluid | |
Kerber et al. | Calibrated leak balloon microcatheter: a device for arterial exploration and occlusive therapy | |
Back et al. | Angiography with carbon dioxide (CO2) | |
JP2013133336A (en) | Contrast medium composition including high concentration contrast medium and exhibiting high contrast enhancement effect | |
Goto et al. | Permanent inflation of detachable balloons with a low-viscosity, hydrophilic polymerizing system. | |
White Jr et al. | Therapeutic embolization with detachable balloons: physical factors influencing permanent occlusion | |
Ali et al. | Use of carbon dioxide as an intravascular contrast agent: A review of current literature | |
US20050145258A1 (en) | Composition, Method and Device for Blood Supply Fluctuation Therapy | |
Krajina et al. | Wedged hepatic venography for targeting the portal vein during TIPS: comparison of carbon dioxide and iodinated contrast agents | |
Paramasivam et al. | O-015 image guided bleomycin sclerotherapy for orbital lymphatic malformation | |
Torné et al. | Safety and feasibility assessment of the O-Arm as an intraoperative angiography device in aneurysm surgery | |
RU2613888C1 (en) | METHOD FOR PREOPERATIVE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER AT T1b2-T2b STAGE | |
Patelis et al. | Physiology of intraluminal administration of Carbon Dioxide as a contrast medium | |
CN113546234B (en) | Medicinal preparation with tracing function for vascular intervention and its delivery system | |
Muldoon et al. | Anaesthesia for interventional neuroradiology | |
Ali et al. | World Journal of | |
Ali et al. | WJC | |
US20240165294A1 (en) | Tunable, stable sclerosing foam for vascular interventions | |
JP2019048779A (en) | Contrast medium for ultrasonic diagnosis | |
Eldem et al. | Contrast Agents in Vascular Interventional Radiology | |
Sun et al. | Fine-needle percutaneous transhepatic parenchymal portal venography by using carbon dioxide: a pilot study in pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |